Autologous formalin-fixed tumor vaccine for initially-diagnosed glioblastoma

Takashi Maruyama; Yoshihiro Muragaki; Eiichi Ishikawa; Koji Tsuboi; Hiroshi Iseki; Tadao Ohno; Akira Matsumura; Yoshikazu Okada

Autologous formalin-fixed tumor vaccine for initially-diagnosed glioblastoma

Takashi Maruyama^*, Yoshihiro Muragaki, Eiichi Ishikawa, Koji Tsuboi, Hiroshi Iseki, Tadao Ohno, Akira Matsumura, Yoshikazu Okada

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract

There has been little improvement in the prognosis of glioblastoma multiforme (GBM) despite a number of therapeutic modalities that have been developed. Immunotherapy presents a therapeutic challenge with a different strategy from radiation therapy and chemotherapy. Based on the tumor-specific immune reactions, Ohno's group developed the use of formalin-fixed sections instead of live target tumor cells and formulated an autologous formalin-fixed tumor vaccine (AFTV). This paper reports the results of preliminary clinical trials and prospective clinical trial directed to the evaluation of the therapeutic efficacy of the AFTV concomitant with fractionated radiotherapy (FRT) in cases of initially-diagnosed glioblastoma multiforme (GBM).

Original language	English
Pages (from-to)	448-455
Number of pages	8
Journal	Biotherapy
Volume	24
Issue number	6
Publication status	Published - 2010 Nov
Externally published	Yes

Keywords

Autologous formalin-fixed tumor vaccine
Clinical trial
Glioblastoma

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{675970d35d144b8092ceee69b9ffc9ff,

title = "Autologous formalin-fixed tumor vaccine for initially-diagnosed glioblastoma",

abstract = "There has been little improvement in the prognosis of glioblastoma multiforme (GBM) despite a number of therapeutic modalities that have been developed. Immunotherapy presents a therapeutic challenge with a different strategy from radiation therapy and chemotherapy. Based on the tumor-specific immune reactions, Ohno's group developed the use of formalin-fixed sections instead of live target tumor cells and formulated an autologous formalin-fixed tumor vaccine (AFTV). This paper reports the results of preliminary clinical trials and prospective clinical trial directed to the evaluation of the therapeutic efficacy of the AFTV concomitant with fractionated radiotherapy (FRT) in cases of initially-diagnosed glioblastoma multiforme (GBM).",

keywords = "Autologous formalin-fixed tumor vaccine, Clinical trial, Glioblastoma",

author = "Takashi Maruyama and Yoshihiro Muragaki and Eiichi Ishikawa and Koji Tsuboi and Hiroshi Iseki and Tadao Ohno and Akira Matsumura and Yoshikazu Okada",

year = "2010",

month = nov,

language = "English",

volume = "24",

pages = "448--455",

journal = "Biotherapy",

issn = "0914-2223",

publisher = "Japanese Society for Cancer Chemotherapy",

number = "6",

}

TY - JOUR

T1 - Autologous formalin-fixed tumor vaccine for initially-diagnosed glioblastoma

AU - Maruyama, Takashi

AU - Muragaki, Yoshihiro

AU - Ishikawa, Eiichi

AU - Tsuboi, Koji

AU - Iseki, Hiroshi

AU - Ohno, Tadao

AU - Matsumura, Akira

AU - Okada, Yoshikazu

PY - 2010/11

Y1 - 2010/11

N2 - There has been little improvement in the prognosis of glioblastoma multiforme (GBM) despite a number of therapeutic modalities that have been developed. Immunotherapy presents a therapeutic challenge with a different strategy from radiation therapy and chemotherapy. Based on the tumor-specific immune reactions, Ohno's group developed the use of formalin-fixed sections instead of live target tumor cells and formulated an autologous formalin-fixed tumor vaccine (AFTV). This paper reports the results of preliminary clinical trials and prospective clinical trial directed to the evaluation of the therapeutic efficacy of the AFTV concomitant with fractionated radiotherapy (FRT) in cases of initially-diagnosed glioblastoma multiforme (GBM).

AB - There has been little improvement in the prognosis of glioblastoma multiforme (GBM) despite a number of therapeutic modalities that have been developed. Immunotherapy presents a therapeutic challenge with a different strategy from radiation therapy and chemotherapy. Based on the tumor-specific immune reactions, Ohno's group developed the use of formalin-fixed sections instead of live target tumor cells and formulated an autologous formalin-fixed tumor vaccine (AFTV). This paper reports the results of preliminary clinical trials and prospective clinical trial directed to the evaluation of the therapeutic efficacy of the AFTV concomitant with fractionated radiotherapy (FRT) in cases of initially-diagnosed glioblastoma multiforme (GBM).

KW - Autologous formalin-fixed tumor vaccine

KW - Clinical trial

KW - Glioblastoma

UR - http://www.scopus.com/inward/record.url?scp=78650848632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650848632&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:78650848632

SN - 0914-2223

VL - 24

SP - 448

EP - 455

JO - Biotherapy

JF - Biotherapy

IS - 6

ER -

Autologous formalin-fixed tumor vaccine for initially-diagnosed glioblastoma

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Other files and links

Fingerprint

Cite this